AG 348

Drug Profile

AG 348

Alternative Names: AG-348

Latest Information Update: 06 Jul 2017

Price : $50

At a glance

  • Originator Agios Pharmaceuticals
  • Class Antianaemics; Small molecules
  • Mechanism of Action Pyruvate kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inborn error metabolic disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Haemolytic anaemia

Most Recent Events

  • 27 Jun 2017 Updated safety and efficacy data from phase II DRIVE-PK trial in Haemolytic anaemia (associated with pyruvate kinase deficiency) were presented at the 22nd Congress of the European Haematology Association (EHA-2017)
  • 04 May 2017 Agios Pharmaceuticals plans global pivotal trial for Haemolytic anaemia (Pyruvate kinase deficiency) in the first half of 2018
  • 27 Apr 2017 AG 348 receives Fast Track designation for Haemolytic anaemia (Pyruvate kinase deficiency) [PO] in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top